SAN CARLOS, Calif.– TRIO Pharmaceuticals, a biotechnology company developing multi-functional antibody therapies for cancers with high unmet medical need, announced that Mikael Dolsten, M.D., Ph.D., has joined the company as Chairman of the Board of Directors. Dr. Dolsten will also serve as an independent director.
“I am thrilled to join a company developing truly innovative treatments for cancer,” said Dr. Dolsten. “The potential to counter resistance and kill cancer cells while minimizing harm to other normal cells in the body is an exciting approach with breakthrough potential.”
Dr. Dolsten brings more than three decades of leadership and scientific experience in global biopharma. He most recently served for over 15 years as Chief Scientific Officer and President of Research and Development at Pfizer Inc., where he was also a member of the company’s Executive Leadership Team. During his tenure, Pfizer achieved more than 36 drug approvals across antibodies, small molecules, vaccines, and generic medicines.
Before joining Pfizer, Dr. Dolsten held senior research and leadership positions at Wyeth Research, Boehringer Ingelheim, AstraZeneca, and Pharmacia, contributing to approximately 50 drug and vaccine approvals and participating in transactions totaling more than $100 billion in combined value.
In addition to his executive experience, Dr. Dolsten has served on numerous public and private boards, including Agilent Technologies, Novo Nordisk, Rocket Pharmaceuticals, Orbis Medicine, ChAi Discovery, Fair Journey Biologics, and Arbor Biotechnologies. He currently advises major investment firms such as Blackstone Life Sciences, GV (Google Ventures), Canaan Partners, and Bain & Co., and collaborates with public health institutions including the Scripps Research Institute and the Foundation for the National Institutes of Health.
“Mikael is a scientist and executive with a rare combination of entrepreneurial scientific acumen and business leadership skills,” said Patrick Doyle, Chief Executive Officer of TRIO Pharmaceuticals. “We are honored to have him join TRIO at a key point in our development of our TRAILBody antibodies for direct killing of cancer cells and other applications.”
Shiva Bhowmik, Ph.D., President, Chief Scientific Officer, and Founder of TRIO, added, “We are excited to have Dr. Dolsten join our board. His extensive experience in drug development, particularly in oncology, will greatly strengthen our scientific and clinical strategy.”
Dr. Dolsten has authored more than 150 peer-reviewed scientific papers and is widely recognized for his contributions to oncology, inflammation, and molecular biology. During the COVID-19 pandemic, he served as the scientific leader for the development of Pfizer’s mRNA-based vaccine and its oral antiviral treatment, Paxlovid.
